![]() "he is the basic science officer of the special interest group in implantation and early pregnancy (SIGIEP) of the European Society of Human Reproduction and Embryology (ESHRE)".įrancesca Benini is a senior embryologist at Demetra center, GeneraLife IVF. "He is part of the Executive Committee of the Italian Society of Embryology, Reproduction and Research (SIERR)", He is associate editor of the journal Human Reproduction Update". ![]() He received paid consultations from Merck KGaA. He received paid lectures from Fujifilm-Irvine Scientific. ![]() Laura Girardi is a full time employee of Igenomix Italy.ĭanilo Cimadomo is a full-time employee of GeneraLife IVF, where he is the Science and Research Manager. She is partner/shareholder of Global Investment Clinics s.a'.r.l., Genera Health Care srl and Nterilizer, and has been of Flam srl. She has received honoraria/consultation fees by Merck KGaA, MSD, Ferring, Ibsa, Cooper Surgical, Cook, Nterilizer, Fujifilm-Irvine Scientific, Medea and Universal clinics. She has been the principal investigator of a study sponsored by Merck KGaA. She is Editor of Reproductive BioMedicine Online and has been Associate Editor of Human Reproduction Update. Laura Rienzi is the Scientific Director of GeneraLife IVF. Maurizio Poli is a full time employee of Igenomix Italy. (Funded by Igenomix number, NCT03673592) Competing Interest StatementĪntonio Capalbo is a full time employee of Igenomix Italy. Moreover, dismissing these embryos from clinical use has the counterproductive effect of reducing overall embryo availability, thus reducing the chance of successful outcome derived from an IVF treatment without any clinical benefit. Should the embryos with low or moderate-degree mosaic TE biopsies had been classified as chromosomally abnormal and thus discarded for clinical use, LBR per cycle would have decreased by 36% without any clinical benefit.Ĭonclusions This prospective non-selection trial provides substantial evidence that reporting and/or not transferring embryos with low/moderate-degree mosaicism for whole chromosomes have no clinical utility. Neonatal karyotypes were also similar and no instances of mosaicism or uniparental disomies (UPDs) were detected in babies born following putative low or moderate-degree mosaic embryo transfer. Likewise, no statistically significant difference was observed comparing moderate versus low degree mosaic embryos (P=0.92). The non-inferiority endpoint was met as the confidence interval for the difference fell below the planned 7.5% margin (95% C.I. No difference was detected for this primary outcome between euploid and mosaic low/moderate categories (OR= 0.96 95% CI 0.743 to 1.263 P=0.816). All rights reserved.Results LBR after transfer of uniformly euploid embryos, low-degree, and moderate-degree mosaic embryos were 43.4% (95% C.I. Neonatal outcomes did not differ significantly between the euploid and mosaic groups.Įmbryonic mosaicism Next-generation sequencing Preimplantation genetic testing for aneuploidies (PGT-A) Segmental aneuploidy Trophectoderm biopsy.Ĭopyright © 2022 Reproductive Healthcare Ltd. Mosaic embryos with a high aneuploidy percentage (≥60%) should be assigned a low transfer priority. Mosaic embryos were associated with a lower LBR, while segmental mosaic embryos had similar clinical outcomes to euploid embryos. Of the 34 women with a live birth after MET, 13 had a prenatal or postnatal genetic testing result, and no abnormalities were found. Neonatal outcomes did not differ significantly between the mosaic and euploid groups. Mosaic embryos with a high percentage of aneuploid cells (≥60%) showed a significantly lower LBR (10.5% versus 40.7%, P = 0.03) than euploid embryos after covariate adjustment, with three of the five implantations of mosaic embryos resulting in miscarriage. Segmental mosaic embryos had an implantation rate (47.5%) and LBR (45.0%) comparable to those of euploid embryos. Overall, EET resulted in a significantly higher implantation rate (47.0%) and LBR (40.7%) than MET (implantation rate 39.0%, P = 0.005 LBR 28.8%, P = 0.008) and WCM embryos (implantation rate 37.5%, P = 0.01 LBR 22.2%, P = 0.007) after covariate adjustment. Trophectoderm biopsies were classified as mosaic if they had 20-80% abnormal cells. Blastocysts were analysed using preimplantation genetic testing for aneuploidies with next-generation sequencing, followed by a single vitrified-warmed embryo transfer. This retrospective cohort study compared the implantation rate, live birth rate (LBR) and miscarriage rate between 513 euploid embryos and 118 mosaic embryos (72 whole chromosome mosaic, 40 segmental mosaic and six complex mosaic). Do clinical and neonatal outcomes differ between mosaic embryo transfers (MET) and euploid embryo transfers (EET)?
0 Comments
Leave a Reply. |